Administered via pulmonary delivery, Que-lipo regulated the expression of key apoptosis-associated proteins such as Bcl-2 and caspase-3/7, leading to significant inhibition of apoptotic activity in COPD. Here, BCL2 is linked to chronic obstructive pulmonary disease.